Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs

The newly launched I-SPY 2 trial will put into practice many ideas about adaptive trial design and the use of biomarkers for patient selection, and it could herald the coming of a new model of drug development.